SUPPLY AND LICENSE AGREEMENT BETWEENSupply and License Agreement • July 20th, 2021
Contract Type FiledJuly 20th, 2021This Supply and License Agreement (the “Agreement”) is entered into and made effective as of July 30, 2020 (the “Effective Date”), by and between Serum Institute of India Private Limited., an Indian company having its principal place of business at 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028 (“SIIPL”, which expression shall, unless repugnant to the context thereof, mean and include its successors and permitted assigns), and Novavax, Inc., a Delaware, USA corporation having its principal place of business at 21 Firstfield Road, Gaithersburg, MD 20878 USA (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates). Novavax and SIIPL may each be referred to herein individually as a “Party” and collectively as the “Parties.”
SUPPLY AND LICENSE AGREEMENT BETWEEN SERUM INSTITUTE OF INDIA PRIVATE LIMITED AND NOVAVAX, INC. Dated: 30 July, 2020Supply and License Agreement • February 2nd, 2021
Contract Type FiledFebruary 2nd, 2021This Supply and License Agreement (the “Agreement”) is entered into and made effective as of July 30, 2020 (the “Effective Date”), by and between Serum Institute of India Private Limited., an Indian company having its principal place of business at 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028 (“SIIPL”, which expression shall, unless repugnant to the context thereof, mean and include its successors and permitted assigns), and Novavax, Inc., a Delaware, USA corporation having its principal place of business at 21 Firstfield Road, Gaithersburg, MD 20878 USA (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates). Novavax and SIIPL may each be referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUPPLY AND LICENSE AGREEMENT BETWEEN SERUM INSTITUTE OF INDIA PRIVATE...Supply and License Agreement • November 10th, 2020 • Novavax Inc • Biological products, (no disgnostic substances)
Contract Type FiledNovember 10th, 2020 Company IndustryThis Supply and License Agreement (the “Agreement”) is entered into and made effective as of July 30, 2020 (the “Effective Date”), by and between Serum Institute of India Private Limited., an Indian company having its principal place of business at 212/2, Off Soli Poonawalla Road, Hadapsar, Pune 411028 (“SIIPL”, which expression shall, unless repugnant to the context thereof, mean and include its successors and permitted assigns), and Novavax, Inc., a Delaware, USA corporation having its principal place of business at 21 Firstfield Road, Gaithersburg, MD 20878 USA (“Novavax”, which expression shall, unless repugnant to the context thereof, mean and include its Affiliates). Novavax and SIIPL may each be referred to herein individually as a “Party” and collectively as the “Parties.”